Editas Medicine, Inc. (NASDAQ: EDIT) is a Healthcare company (Biotechnology) with a market capitalization of $282M. The Maz Rating grades it against the other companies in its sector.
Editas Medicine, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.82, Editas Medicine, Inc. trades at 5.7x sales and 3.3x book value. Over the last twelve months it generated about $50M of revenue and a net loss of $95M. It runs a gross margin of 99.0%, an operating margin of -164.3% and a net margin of -145.0%. It shows return on equity of -130.4%, return on invested capital of -53.0% and a free cash flow yield of -39.0%. On the balance sheet: a debt-to-equity ratio of 0.16 and a current ratio of 2.82. Over the past 52 weeks the share price ranged from $1.66 to $3.94, with a beta of 2.08.
Editas Medicine, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 16 Buy, 8 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Editas Medicine, Inc. (EDIT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 57.0% / 30% · Interest income / Revenue 19.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 57.0% / 33% · Receivables / Mkt Cap (36m) 2.32% / 49% · Interest income / Revenue 19.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 57.0% / 33.33% · Receivables / Mkt Cap (24m) 2.32% / 33.33% · Interest income / Revenue 19.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 15.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 84.8% / 33.33% · Receivables / Avg Assets (4Q) 3.56% / 33.33% · Interest income / Revenue 19.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 86.7% / 33.33% · (Cash+Recv) / Total Assets 90.2% / 33.33% · Interest income / Revenue 19.0% / 5% | Fail |
No. As of September 2026, Editas Medicine, Inc. (EDIT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Editas Medicine, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 19.0% of each dividend: Editas Medicine, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.